<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024271</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068907</org_study_id>
    <secondary_id>CPMC-IRB-13799</secondary_id>
    <secondary_id>NCI-G01-2015</secondary_id>
    <nct_id>NCT00024271</nct_id>
  </id_info>
  <brief_title>Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer</brief_title>
  <official_title>Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Irving Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving the drugs directly into the tumor after surgery and&#xD;
      combining them with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining surgery, chemotherapy, and&#xD;
      radiation therapy in treating patients who have peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate, duration of response, and duration of survival of patients&#xD;
           with peritoneal mesothelioma treated with surgery, intraperitoneal chemotherapy, and&#xD;
           whole abdominal radiotherapy.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo initial surgery, including total omentectomy and excision of gross&#xD;
      disease. Approximately 3-4 weeks after surgery, patients receive intraperitoneal (IP)&#xD;
      chemotherapy consisting of doxorubicin IP over 2 hours once weekly on weeks 1, 4, 7, and 10&#xD;
      and cisplatin IP and gemcitabine IP once weekly on weeks 2, 5, 8, and 11. Patients also&#xD;
      receive interferon gamma IP once weekly on weeks 13-16.&#xD;
&#xD;
      At approximately week 18-20, patients undergo second-look surgery. Patients with no gross&#xD;
      disease receive hyperthermia mitomycin IP and cisplatin IP over 90 minutes.&#xD;
&#xD;
      Approximately 2-4 weeks after second-look surgery, patients undergo radiotherapy 5 days a&#xD;
      week for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 3 years, and then&#xD;
      annually for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon gamma</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperthermia treatment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant mesothelioma&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Ineligible for other high-priority study&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 45 mL/min&#xD;
&#xD;
          -  BUN less than 1.5 times normal&#xD;
&#xD;
          -  No significant calcium abnormalities&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic cardiovascular disease&#xD;
&#xD;
          -  No New York Heart Association class II, III, or IV heart disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No significant phosphate, electrolyte, or other metabolic abnormalities (e.g.,&#xD;
             metabolic acidosis)&#xD;
&#xD;
          -  No uncontrolled psychiatric disorder or neurologic disease&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ of the cervix or skin cancer&#xD;
&#xD;
          -  No other serious medical or psychiatric illness&#xD;
&#xD;
          -  No uncontrolled serious infection&#xD;
&#xD;
          -  No senility or emotional instability&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  No more than 1 prior intraperitoneal chemotherapy regimen&#xD;
&#xD;
          -  More than 6 weeks since prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy except for nondisease-related conditions (e.g., insulin&#xD;
             for diabetes)&#xD;
&#xD;
          -  Concurrent steroids for antiemesis, premedication, adrenal failure, or septic shock&#xD;
             allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior abdominal, pelvic, or lower chest radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgical resection preceding disease recurrence allowed&#xD;
&#xD;
          -  More than 1 week since prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert N. Taub, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2004</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

